West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
This story was originally published by cnbc.com. Use the link below to read the full article at the source.
Share
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
